Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Rating Reiterated by BMO Capital Markets

BMO Capital Markets restated their outperform rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a report issued on Wednesday, July 12th. BMO Capital Markets currently has a $62.00 price target on the stock, up from their prior price target of $59.00.

Other research analysts have also recently issued research reports about the stock. Cowen and Company restated a market perform rating on shares of Ionis Pharmaceuticals in a report on Monday, May 22nd. Vetr cut shares of Ionis Pharmaceuticals from a hold rating to a sell rating and set a $37.67 price objective for the company. in a report on Monday, April 3rd. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a hold rating to a buy rating and set a $58.00 price objective for the company in a report on Wednesday, July 12th. Stifel Nicolaus restated a hold rating and issued a $42.00 price objective on shares of Ionis Pharmaceuticals in a report on Monday, July 10th. Finally, Needham & Company LLC restated a buy rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $45.38.

Shares of Ionis Pharmaceuticals (IONS) traded down 4.14% on Wednesday, hitting $52.08. 1,650,328 shares of the stock traded hands. Ionis Pharmaceuticals has a one year low of $24.58 and a one year high of $59.71. The company’s 50 day moving average is $52.77 and its 200 day moving average is $46.68. The stock’s market cap is $6.46 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Tuesday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The business had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The business’s revenue was up 199.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.52) EPS. On average, equities analysts forecast that Ionis Pharmaceuticals will post ($0.27) EPS for the current year.

WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/07/27/ionis-pharmaceuticals-nasdaqions-outperform-rating-reiterated-at-bmo-capital-markets-updated.html.

In other news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the business’s stock in a transaction on Wednesday, July 19th. The stock was bought at an average price of $8.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the insider now owns 28,884,540 shares in the company, valued at $231,076,320. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Stanley T. Crooke sold 16,500 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $52.10, for a total transaction of $859,650.00. Following the transaction, the chairman now owns 51,476 shares of the company’s stock, valued at approximately $2,681,899.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,029 shares of company stock valued at $2,977,740. 1.86% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in IONS. Hanseatic Management Services Inc. bought a new position in Ionis Pharmaceuticals during the first quarter worth $138,000. Westpac Banking Corp bought a new position in Ionis Pharmaceuticals during the first quarter worth $171,000. Cheyne Capital Management UK LLP bought a new position in Ionis Pharmaceuticals during the second quarter worth $249,000. Capstone Asset Management Co. boosted its position in Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the period. Finally, World Asset Management Inc boosted its position in Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after buying an additional 1,163 shares during the period. Institutional investors own 88.75% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

What are top analysts saying about Ionis Pharmaceuticals Inc.? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Ionis Pharmaceuticals Inc. and related companies.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

eighteen − 7 =